Ligand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024. In the quarter to June 2026, revenue grew 33.7%, EPS grew 868.0% and free cash flow grew 35.5%, each against the same quarter a year earlier.
Follow LGND
Ligand Pharmaceuticals Incorporated (LGND) Piotroski F-score
Ligand Pharmaceuticals Incorporated's Piotroski F-score for fiscal 2025 is 6 out of 9: 6 of nine tests of profitability, leverage and efficiency passed, up from 5 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 6 | 1.00 |
| FY2024 | 5 | (1.00) |
| FY2023 | 6 | 2.00 |
| FY2022 | 4 | (3.00) |
| FY2021 | 7 | 2.00 |
| FY2020 | 5 | 0.00 |
| FY2019 | 5 | (2.00) |
| FY2018 | 7 | (1.00) |
| FY2017 | 8 | 3.00 |
| FY2016 | 5 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 9.95% | (0.47%) | Pass | 1 |
| Positive operating cash flow | 49.36m | 97.05m | Pass | 1 |
| Rising return on assets | 9.95% | (0.47%) | Pass | 1 |
| Cash flow above net income | (75.09m) | 101.08m | Fail | 0 |
| Falling long-term leverage | 0.36 | 0.00 | Fail | 0 |
| Rising current ratio | 22.23 | 8.93 | Pass | 1 |
| No new shares issued | 19,338,000 | 18,290,000 | Fail | 0 |
| Rising gross margin | 94.57% | 93.37% | Pass | 1 |
| Rising asset turnover | 0.21 | 0.19 | Pass | 1 |
| Piotroski F-score | Mixed | 6 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| RYTM Rhythm Pharmaceuticals, Inc. compare | 6 |
| LGND Ligand Pharmaceuticals Incorporated | 6 |
| MIRM Mirum Pharmaceuticals, Inc. compare | 6 |
| IOVA Iovance Biotherapeutics, Inc. compare | 4 |
| CGON CG Oncology, Inc. compare | 2 |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| ERAS Erasca, Inc. compare | — |
| IMVT Immunovant, Inc. compare | — |
| KOD Kodiak Sciences Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover